Literature DB >> 16237752

1.5 Harmonic Imaging Sonography with microbubble contrast agent improves characterization of hepatocellular carcinoma.

Kouji Yamamoto1, Katsuya Shiraki, Shigeo Nakanishi, Hiroyuki Fuke, Takeshi Nakano, Akira Hashimoto, Atsuya Shimizu, Toshinobu Hamataki.   

Abstract

AIM: To investigate the usefulness of 1.5 Harmonic Imaging Sonography with the use of the contrast agent Levovist for the diagnosis of hepatocellular carcinoma (HCC) and for the evaluation of therapeutic response.
METHODS: Phantom experiments were performed to compare the contrast effects of 2(nd) harmonic imaging and 1.5 Harmonic Imaging Sonography. 1.5 Harmonic Imaging Sonography was employed to examine 36 patients with HCC (42 nodules) before and after the treatment and to compare against the findings obtained using other diagnostic imaging modalities.
RESULTS: In 1.5 Harmonic Imaging Sonography, the tumor vessels of HCCs were clearly identified during the early phase, and late-phase images clearly demonstrated the differences in contrast enhancement between the tumor and surrounding hepatic parenchyma. Blood flow within the tumor was detected in 36 nodules (85.7%) during the early phase and in all 42 nodules (100%) during the late phase using 1.5 Harmonic Imaging Sonography, in 38 nodules (90.5%) using contrast-enhanced CT, in 34 nodules (81.0%) using digital subtraction angiography (DSA), and in 42 nodules (100%) using US CO(2) angiography. Following transcatheter arterial embolization, 1.5 Harmonic Imaging Sonography detected blood flow and contrast enhancement within the tumors that were judged to contain viable tissue in 20 of 42 nodules (47.6%). However, 6 of these 10 cases were not judged in contrast-enhanced CT. 1.5 Harmonic Imaging Sonography was compared with the US CO(2) angiography findings as the gold standard, and the sensitivity and specificity of these images for discerning viable and nonviable HCC after transcatheter arterial embolization were 100% and 100%, respectively.
CONCLUSION: 1.5 Harmonic Imaging Sonography permits the vascular structures of HCCs to be identified and blood flow within the tumor to be clearly demonstrated. Furthermore, 1.5 Harmonic Imaging Sonography is potentially useful for evaluating the therapeutic effects of transcatheter arterial embolization on HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237752      PMCID: PMC4481475          DOI: 10.3748/wjg.v11.i36.5607

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  Limitations of characterization of hepatic hemangiomas using a sonographic contrast agent (Levovist) and power Doppler ultrasonography.

Authors:  T K Kim; J K Han; A Y Kim; B I Choi
Journal:  J Ultrasound Med       Date:  1999-11       Impact factor: 2.153

2.  Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT.

Authors:  H Ding; M Kudo; H Onda; Y Suetomi; Y Minami; H Chung; T Kawasaki; K Maekawa
Journal:  Radiology       Date:  2001-12       Impact factor: 11.105

3.  Hepatic malignancies: improved detection with pulse-inversion US in late phase of enhancement with SH U 508A-early experience.

Authors:  C J Harvey; M J Blomley; R J Eckersley; D O Cosgrove; N Patel; R A Heckemann; J Butler-Barnes
Journal:  Radiology       Date:  2000-09       Impact factor: 11.105

4.  Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience.

Authors:  M J Blomley; T Albrecht; D O Cosgrove; N Patel; V Jayaram; J Butler-Barnes; R J Eckersley; A Bauer; R Schlief
Journal:  Radiology       Date:  1999-02       Impact factor: 11.105

Review 5.  Ultrasound contrast agents: basic principles.

Authors:  F Calliada; R Campani; O Bottinelli; A Bozzini; M G Sommaruga
Journal:  Eur J Radiol       Date:  1998-05       Impact factor: 3.528

6.  Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results.

Authors:  D Choi; H K Lim; S H Kim; W J Lee; H J Jang; J Y Lee; S W Paik; K C Koh; J H Lee
Journal:  Radiology       Date:  2000-11       Impact factor: 11.105

7.  Liver lesions: intermittent second-harmonic gray-scale US can increase conspicuity with microbubble contrast material-early experience.

Authors:  R A Heckemann; D O Cosgrove; M J Blomley; R J Eckersley; C J Harvey; Y Mine
Journal:  Radiology       Date:  2000-08       Impact factor: 11.105

8.  Hepatic focal nodular hyperplasia: specific findings at dynamic contrast-enhanced US with carbon dioxide microbubbles.

Authors:  M Kudo; S Tomita; H Tochio; H Kashida; M Hirasa; A Todo
Journal:  Radiology       Date:  1991-05       Impact factor: 11.105

9.  Hepatocellular carcinoma: power Doppler US with a contrast agent--preliminary results.

Authors:  A Y Kim; B I Choi; T K Kim; J K Han; E J Yun; K Y Lee; M C Han
Journal:  Radiology       Date:  1998-10       Impact factor: 11.105

10.  Diagnosis of hepatocellular carcinoma using digital subtraction imaging with the contrast agent, Levovist: comparison with helical CT, digital subtraction angiography, and US angiography.

Authors:  Kouji Yamamoto; Katsuya Shiraki; Masatoshi Deguchi; Kazushi Sugimoto; Takahisa Sakai; Shigeru Ohmori; Kazumoto Murata; Akira Hashimoto; Atsuya Shimizu; Yoshiro Okuda; Takeshi Nakano
Journal:  Oncol Rep       Date:  2002 Jul-Aug       Impact factor: 3.906

View more
  1 in total

1.  Delta-projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion.

Authors:  Chandra M Sehgal; Theodore W Cary; Peter H Arger; Andrew K W Wood
Journal:  Acad Radiol       Date:  2009-01       Impact factor: 3.173

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.